SYNGENE - Syngene International

Syngene International

SYNGENE · Pharma > Pharmaceuticals & Drugs · Chairman: Kiran Mazumdar Shaw · MD: Jonathan Hunt · Listing date: Aug. 11, 2015 · Employees: 5437 · Bangalore · http://www.syngeneintl.com

Stock Price vs Company Growth

2.8%

7.0%

7.7%

4.0%

8.7%

37.5%

8.0%

10y

4.7%

all

8.9%

🤔 How to analyze this graph?

Last Traded Price

₹ 398 2.8%

345

420

Company Overview

Sales

3,600 Cr

Growth: 2.5%

Profit after Tax

221 Cr

Growth: -30.2%

Mid Cap

15,938 Cr

P/E: 72.4x

Industry P/E: 32.5x

Fundamentals

Sales (Cr)	₹ 3,600
Growth	2.5%
EBITDA	22.3%
P/S	4.5x
Dividend	0.2%
P/E	72.4x
Book Value	₹ 120
PEG Ratio	27.7x
ROE	4.5%
P/B	3.2x

Shareholding Pattern

Institutions

Government Pension Fund Global

1.14 %

Uti-Mid Cap Fund

1.03 %

Qualified Institutional Buyer

0.15 %

Promoters

Biocon Limited

70.1 %

Biocon Limited Employee Welfare Trust (Murali Krishnan K N And Amitava Saha)

0.32 %

Yamini R Mazumdar

0.01 %

Others

Increase Decrease No change

Company Profile Detailed

The company is a contract research, development, and manufacturing services company that offers a broad range of scientific services from the earliest stages of discovery to commercial supplies. This positions the Company as an end-to-end service provider within its sector.

Belongs to (29 Indices) view more

Investors (435)

mahesh.g...

ajit.man...

kiran.ku...

Followers (15)

yogesh

nitin2

keerthi